Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Capital Expenditures (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Capital Expenditures for 11 consecutive years, with -$75000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures changed N/A to -$75000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$20000.0, a N/A change, with the full-year FY2025 number at $11000.0, up 10.31% from a year prior.
  • Capital Expenditures was -$75000.0 for Q4 2025 at Crescent Biopharma, down from $47561.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $47561.0 in Q2 2025 to a low of -$75000.0 in Q4 2025.
  • A 5-year average of $6701.9 and a median of $4334.0 in 2021 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: tumbled 99.96% in 2022, then soared 80000.0% in 2023.
  • Crescent Biopharma's Capital Expenditures stood at $2447.0 in 2021, then crashed by 99.96% to $1.0 in 2022, then skyrocketed by 80000.0% to $801.0 in 2023, then skyrocketed by 828.71% to $7439.0 in 2024, then tumbled by 1108.2% to -$75000.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Capital Expenditures are -$75000.0 (Q4 2025), $47561.0 (Q2 2025), and $7439.0 (Q1 2024).